The Biologics Safety Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Products and Services (Consumables, Instrument, Services), By Application (Vaccine Development and Manufacturing, Monoclonal Antibodies Development and Manufacturing, Cellular & Gene Therapy Products Development and Manufacturing, Blood and Blood Products Development and Manufacturing, Others), By Test (Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-cell Proteins & DNA Detection Tests, Virus safety Test, Others).
Biologics safety testing is a crucial step in the development and manufacturing of biopharmaceutical products to ensure their safety, purity, and potency for clinical use. In 2024, biologics safety testing encompasses a battery of assays and analyses to evaluate the presence of contaminants, impurities, and adventitious agents in biologics, including monoclonal antibodies, vaccines, and gene therapies. These tests include cell-based assays, nucleic acid amplification tests, protein analysis, and animal studies, tailored to specific product characteristics and regulatory requirements. Biologics safety testing aims to detect potential risks such as microbial contamination, host cell protein impurities, and viral vectors to mitigate the potential for adverse effects in patients. With advancements in analytical techniques, molecular biology tools, and quality control standards, biologics safety testing continues to evolve, ensuring the quality and safety of biopharmaceutical products throughout their lifecycle. As biologics play an increasingly important role in modern medicine, robust safety testing protocols are essential to maintaining public trust and ensuring patient safety.
One prominent trend in the biologics safety testing market is the increasing stringency of regulatory requirements. As the biopharmaceutical industry continues to expand, regulatory agencies are imposing stricter guidelines and standards for the safety testing of biologics products. This includes rigorous testing for contaminants, impurities, and adventitious agents to ensure the safety and efficacy of biologics drugs and vaccines. The trend towards more comprehensive and stringent regulatory oversight drives the demand for advanced analytical techniques, innovative testing methods, and robust quality control measures in biologics safety testing, shaping the landscape of regulatory compliance and quality assurance in the biopharmaceutical sector.
A significant driver in the biologics safety testing market is the growing demand for biologics products. Biologics, including monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies, are increasingly being used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. With the expanding pipeline of biologics drugs and the shift towards targeted therapies and personalized medicine, there is a rising need for comprehensive safety testing to assess the purity, potency, and safety profiles of biologics products throughout the drug development and manufacturing process. The increasing demand for biologics products drives the demand for biologics safety testing services, creating opportunities for contract testing laboratories, analytical instrument manufacturers, and regulatory consultants to support biopharmaceutical companies in meeting regulatory requirements and ensuring product quality and safety.
An emerging opportunity in the biologics safety testing market is the advancements in analytical technologies and testing methods. With rapid developments in analytical instrumentation, automation, and molecular biology techniques, there are opportunities to enhance the efficiency, sensitivity, and throughput of biologics safety testing assays. This includes the adoption of high-throughput screening platforms, next-generation sequencing (NGS), mass spectrometry, and advanced cell-based assays for detecting contaminants, impurities, and adventitious agents in biologics products. Additionally, there is potential to leverage emerging technologies such as artificial intelligence (AI), machine learning (ML), and big data analytics to streamline data analysis, improve predictive modeling, and enhance decision-making in biologics safety testing. By investing in research and development efforts to innovate testing methodologies and analytical solutions, stakeholders in the biologics safety testing market can capitalize on emerging opportunities, address evolving regulatory challenges, and meet the growing demand for safe and effective biologics products in the global healthcare landscape.
Among the segments in the Biologics Safety Testing Market, the Cellular & Gene Therapy Products Development and Manufacturing segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for biologics safety testing services in cellular and gene therapy product development and manufacturing. Cellular and gene therapies hold tremendous promise for treating a wide range of diseases, including cancer, genetic disorders, and autoimmune conditions. However, ensuring the safety and efficacy of these advanced therapies requires rigorous testing and validation to assess their biological activity, purity, and absence of contaminants. Biologics safety testing services, such as endotoxin testing, sterility testing, mycoplasma testing, and residual host-cell proteins & DNA detection tests, play a critical role in verifying the quality and safety of cellular and gene therapy products throughout the development and manufacturing process. Additionally, regulatory agencies impose stringent requirements for the safety and quality control of biologics, further driving the demand for comprehensive safety testing services in cellular and gene therapy product development. As the field of cellular and gene therapy continues to advance and gain regulatory approval for clinical use, the Cellular & Gene Therapy Products Development and Manufacturing segment is expected to sustain its rapid growth in the Biologics Safety Testing Market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossCharles River Laboratories Inc, Eurofins Scientific SE, Laboratory Corp of America Holdings, Lonza Group Ltd, Merck KGaA, SGS S.A., Thermo Fisher Scientific Inc, WuXi AppTec Co. Ltd
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Charles River Laboratories Inc
Eurofins Scientific SE
Laboratory Corp of America Holdings
Lonza Group Ltd
Merck KGaA
SGS S.A.
Thermo Fisher Scientific Inc
WuXi AppTec Co. Ltd
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biologics Safety Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biologics Safety Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Biologics Safety Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Biologics Safety Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Biologics Safety Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biologics Safety Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biologics Safety Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biologics Safety Testing Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Biologics Safety Testing Industry
4.2 Key Market Trends in Biologics Safety Testing Industry
4.3 Potential Opportunities in Biologics Safety Testing Industry
4.4 Key Challenges in Biologics Safety Testing Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Biologics Safety Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Biologics Safety Testing Market Outlook by Segments
7.1 Biologics Safety Testing Market Outlook by Segments, $ Million, 2021- 2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
8 North America Biologics Safety Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Biologics Safety Testing Markets in 2024
8.2 North America Biologics Safety Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biologics Safety Testing Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
9 Europe Biologics Safety Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Biologics Safety Testing Markets in 2024
9.2 Europe Biologics Safety Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biologics Safety Testing Market Size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
10 Asia Pacific Biologics Safety Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Biologics Safety Testing Markets in 2024
10.2 Asia Pacific Biologics Safety Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biologics Safety Testing Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
11 South America Biologics Safety Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Biologics Safety Testing Markets in 2024
11.2 South America Biologics Safety Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biologics Safety Testing Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
12 Middle East and Africa Biologics Safety Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Biologics Safety Testing Markets in 2024
12.2 Middle East and Africa Biologics Safety Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biologics Safety Testing Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Charles River Laboratories Inc
Eurofins Scientific SE
Laboratory Corp of America Holdings
Lonza Group Ltd
Merck KGaA
SGS S.A.
Thermo Fisher Scientific Inc
WuXi AppTec Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Products and Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Biologics Safety Testing Market is one of the lucrative growth markets, poised to register a 12.3% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Charles River Laboratories Inc, Eurofins Scientific SE, Laboratory Corp of America Holdings, Lonza Group Ltd, Merck KGaA, SGS S.A., Thermo Fisher Scientific Inc, WuXi AppTec Co. Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume